FUTURLAB COVID 19 LINE
FOR THE EXCLUSIVE USE OF HEALTHCARE PROFESSIONALS
Futurlab is continuously committed to fighting the Coronavirus through accurate diagnostic and screening solutions dedicated to healthcare professionals.
Our numbers
As cases increase, it becomes crucial to set up rapid tracking systems to break the chain of virus transmission.
Our line includes:
WHAT IT IS
Test diagnostico registrato al Ministero della Salute point-of-care rapido immunocromatografico per la rilevazione dell’Antigene COVID-19 su tampone nasofaringeo. Esso va a ricercare in modo semplice e rapido la proteina Spike o S, antigene specifico conservato nel virus Sars-CoV-2, pertanto indica se al momento della somministrazione l’infezione è in corso.
Diagnostic test registered with the Ministry of Health, this is a point-of-care rapid immunochromatographic test to detect COVID-19 antigens on a nasopharyngeal swab. In works quickly and simply to search for the Spike or S protein, a specific antigen in the Sars-CoV-2 virus, thus indicating if the infection is ongoing at the time of testing.
HOW IT WORKS
The rapid swab test is administered to the patient in the same way as the classic nasopharyngeal swab. The rapid test detects the presence of virus surface proteins or antigens.
ADVANTAGES AND BENEFITS
While the classic swab test requires an average of 24-48 hours to be processed, the rapid test is much faster: you have the result in approximately 15 minutes. This is why they have been introduced for screening purposes, with the aim of monitoring the possible spread of the virus more quickly.
WHAT TO DO IF
If the test comes back positive, it is necessary to perform the RT-PCR molecular confirmation test to look for SARS-CoV-2 RNA.
WHAT IT IS
The COVID-19 IgG/IgM antibody test is an in-vitro qualitative rapid immunochromatographic test registered with the Ministry of Health for the differential detection of SARS-CoV-2 IgG and IgM antibodies in human serum, plasma, or whole blood samples collected via finger prick.
It is designed to help determine recent or previous exposure to SARS-CoV-2 virus, thereby monitoring the patient’s disease status after SARS-CoV-2 infection.
HOW IT WORKS
Capillary whole blood samples may be collected with a finger-prick system. Serum, plasma, or whole blood samples can be taken via venous sampling, according to the facility’s normal procedures.
The sample is placed in the top sample well area on the test device. After approximately 20 seconds, two drops of buffer solution are added to the well, after which the bands may appear.
ADVANTAGES AND BENEFITS
The rapid antibody test is used to detect the presence or absence of antibodies in the blood produced in response to infection. It may thus be used to map the spread of the epidemic in the population.
This type of test is based on a simple blood draw and the results are ready in 15 minutes.
WHAT TO DO IF
A positive result does not necessarily indicate a current infection; it represents a different stage of the disease after infection. Positive IgM or positive IgM / IgG both suggest recent exposure, while positive IgG suggests previous or latent infection. Current infection should be confirmed through RT-PCR, to detect SARS-CoV-2 RNA.
3 products available:
IgA
IgG
IgM
WHAT IT IS
The Covid-19 IgA/IgG/IgM ELISA kit is a test for the qualitative detection of IgA/IgG/IgM-class antibodies against the SARS-CoV-2 virus in human serum or plasma. It is intended to screen patients who may have been infected with SARS-CoV-2 virus and to aid in diagnosing the virus.
HOW IT WORKS
The ELISA kit is a two-step incubation test in which microwells are coated with recombinant SARS-CoV-2 antigens. The patient's serum or plasma sample is added and, during the first incubation, all the anti-SARS-CoV-2 antibodies that may be present in the sample bind to the recombinant antigens in the wells. After washing all other substances from the sample, the SARS-CoV-2 specific IgA/IgG/IgM antibodies bound to the solid phase are detected by adding anti-human IgA/IgG/IgM to form a complex antibody-antibody-HRP enzyme antigen on the surface of the microwells. After the TMB substrate is added, the HRP enzyme converts it into a blue-colored signal. The intensity of the color is directly proportional to the concentration of SARS-Cov-2 IgA/IgM antibodies in the sample.
ADVANTAGES AND BENEFITS
With its exceptional specificity and accuracy, the test provides reliable and reproducible results using the ELISA method. It is suitable for processing a large number of samples.
WHAT TO DO IF
A negative result indicates there are no IgA/IgG/IgM antibodies in the sample. Positive samples should be re-tested and confirmed using alternative tests.
Futurlab offers STRATEGO, the new analyzer completely designed in Italy for the automation of analysis in microplate-based ELISA technology.
Stratego is capable of simultaneously analyzing IgA, IgG and IgM thanks to its three independent plates.
WHAT IT IS
Ready-to-use nasopharyngeal swab system designed for collecting and transporting clinical samples containing viruses or other pathogens.
HOW IT WORKS
Each collection and transport kit includes a sterile bag containing a swab used to collect the sample, a transport tube containing the medium into which the swab is placed after sampling, and a biohazard bag used to contain the tube during transport.
Once a swab sample is collected, it should be placed immediately in the transport tube and delivered to the laboratory as quickly as possible.
ADVANTAGES AND BENEFITS
The classic nasopharyngeal swab with confirmatory molecular testing is still the most accurate tool available to diagnose an ongoing SARS-CoV-2 infection.
The swab system provides a safe and convenient way to transport clinical samples.
WHAT TO DO IF
Your results will depend largely on proper and adequate sample collection, as well as timely transport and processing in the laboratory.
